Product Information:
Retatrutide is an investigational single molecule that activates the body's receptors for three hormones – glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), and is being studied for the treatment of obesity.
At present, the two popular weight loss drugs in the global market are Semaglutide produced by Novo Nordisk and Lilly's own Tirzepatide. However, Semaglutide only targets GLP-1, while Tirzepatide can target GLP-1 and GIP, while Rotarutide is a "triple regulated" molecule that can mimic three different hunger regulating hormones: GLP-1, GIP, and GCG, hence it is called "Triple Hormone Receptor Agnost".
Clinical study:
On June 26, 2023 US time, Eli Lilly published data from a weight loss study funded by Eli Lilly in the New England Journal of Medicine: Retarutide, with a maximum dose of 12mg per week, helped adult obese patients lose an average of 24% of their weight within 48 weeks, which is the best weight loss effect seen so far
This study is a mid-term, double-blind, randomized, placebo-controlled trial involving adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 to less than 30, plus at least one weight related disease. Participants were randomly assigned to receive subcutaneous injection of Retarutide (1mg, 4mg [initial dose, 2mg], 4mg [initial dose, 4mg], 8mg [initial dose, 2mg], 8mg [initial dose, 4mg] or 12mg [initial dose, 2mg]) or placebo once a week for 48 weeks in a 2:1:1:1:1:2:2:2 ratio.
The primary endpoint is the percentage change in weight from baseline to 24 weeks. Secondary endpoints include the percentage change in weight from baseline to 48 weeks, as well as weight loss of 5% or more, 10% or more, or 15% or more. At the same time, safety was also evaluated.
